Author Archive: BIOtechNOW Editor

State of the Biotech Industry: Burrill’s Biotech 2013 Report

Burrill

To open his Super Session at the 2013 BIO International Convention, G. Steven Burrill, CEO of Burrill & Company, injected some humor for the hundreds of attendees in the audience, saying after 45 years in the biotech industry, 27 years authoring the Burrill State-of-the-Industry Report and 20 years of presenting the report at Convention, he was determined to get through 228 slides in 90 minutes. And, he delivered, providing a comprehensive snapshot of the industry Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Scientific American Worldview

Scientific American Worldview

The fifth annual edition of Scientific American Worldview explores ongoing challenges and opportunities in the biopharmaceutical industry, including the looming potential of an “innovation cliff.” Many experts believe that biotechnology remains in its infancy, leaving room for growth. The overall volatility makes it difficult to accurately assess trends within individual countries, but the mission of Worldview is to create an increasingly precise picture of the evolution of biotechnology innovation around the world. One of the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Protect Yourself from a Hack Attack

Protect Yourself from a Hack Attack

Gone are the days when biotech’s biggest activist threats came from lab break-ins and physical attacks. Today almost anyone wishing to damage companies can steal, disrupt or harm employees 24-hours a day and from anywhere in the world. Hackers are anything BUT anonymous Last year the notorious group Anonymous took credit for hacking Monsanto Co. due to the company’s alleged “crimes against humanity.” It was the third hack Anonymous aimed against the the company, and Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Ethics of the Market Access Debate

Rogerio Vivaldi

At the core of the market access conversation lies the question of value. How much do we value two years added to the end of an 80-year-old’s life? How do we put a dollar amount on a medicine that prevents a rare disease patient, who may only live to age 20 regardless of receiving treatment, from losing her ability to walk? How can we define metrics to measure the cost of a child with a Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Managed Entry Trumps Risk Sharing

Since 2000, pharmaceu-tical and biotech companies have engaged in agreements with government and private payers across the world to gain market access for their innovative drugs despite struggles to qualify for formal reimbursement criteria, such as the cost effectiveness threshold from NICE in the UK. These agreements, usually referred to as “risk sharing” agreements, have had a wide variety of structures but usually do not involve any sharing of risk, as the name misleadingly suggests. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,